Floatz logo

2-TRIFLUOROMETHYL-9-(3-(4-(2-HYDROXYETHYL)PIPERAZIN-1-YL)PROPYLIDENE)THIOXANTHENE

Central Nervous System Disorder

Taichung Veterans General HospitalSmall moleculePhase 4 / ApprovedDormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Central Nervous System Disorder cohort.

Asset / SponsorPhaseRating
Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules
Beijing Friendship Hospital
Phase 4BB
3-N-BUTYLPHTHALIDE
Qianfoshan Hospital
Phase 4BB
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4BB
Encenicline
FORUM Pharmaceuticals Inc
Phase 2BB
Donanemab
Eli Lilly and Company
Phase 3BB

View all 50 →

Same molecule, other indications

2-TRIFLUOROMETHYL-9-(3-(4-(2-HYDROXYETHYL)PIPERAZIN-1-YL)PROPYLIDENE)THIOXANTHENE is also rated in:

schizophreniaDormant
B
Indicative · Phase 4
59 / 100
View asset →
physiological malfunction arising from mental factorDormant
B
Indicative · Phase 3
57 / 100
View asset →
anxiety disorderDormant
B
Indicative · Phase 3
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →